Sepsis Clinical Trial
Official title:
Neutrophil FFA2/GPR43 Receptor Expression in Patients With the Diagnosis of Sepsis
This study seeks to elucidate the quantitative expression of G - protein receptor 43/free
fatty acid (GPR43/FFA2) receptors in patients with the diagnosis of sepsis and specifically,
its expression as it relates to the severity of sepsis. The investigators hypothesize that
patients with more severe sepsis, as defined by a higher SOFA (Sequential Organ Failure
Assessment Score), will have decreased expression of the GPR43/FFA2 as compared to patients
with lower SOFA scores, consistent with a less exuberant immune response to infection.
Patients admitted to Penn State Hershey Medical Center with a diagnosis of sepsis of any
cause will undergo blood testing of leukocytes to determine the expressed quantity of GP43
during standardized time points of their illness and recovery. No interventions will be made
in the standard clinical management of the patient. Additionally, healthy volunteers will be
recruited to exam baseline GPR43 receptor expression between sepsis and control groups.
Despite advancements in recognition and treatment, sepsis continues to be a frequently fatal
condition comprising 750,000 cases in the US with an estimated death rate of 28-38%.
Bacterial sepsis complications are the result of a cascade of inflammatory mediators
secondary to the immune system's recognition and response to invading bacteria,
intracellular constituents and metabolites. Bacterial recognition results in the widespread
activation of biological mediators essential to the immune response such as cytokines,
chemokines, prostaglandins and reactive oxygen species. These compounds result in the
activation and up-regulation of neutrophils, monocytes at the cellular level as well as the
physiological changes of sepsis such as hyperpyrexia, vasodilation, and tachycardia. Despite
this generally coordinated response, it is likely that marked complications are related to
the sequela of the uncontrolled immune response leading to significant injury to the lungs
(Acute Respiratory Distress Syndrome), and other organs (acute renal failure, shock liver).
In addition, there is question that impairment of the gut mucosal barrier may result in
translocation of bacteria and perpetuate the multiple organ failure.
G protein-coupled receptors (GPCRs) comprise one of the largest collections of transmembrane
proteins in the mammalian genome. Recently, a subfamily of G protein coupled receptors have
been identified that utilize short chain free fatty acids as ligands, FFA1 (GPR40), FFA2
(GPR43) and FFA3 (GPR41). Research has intimated that these receptors are involved in
essential biological crosstalk between colonic bacteria, host and immune defenses. Although
highly conserved in structure, members of this sub family demonstrate differences in fatty
acid specificity, intracellular signaling mechanisms and tissue localization. Specifically,
FFA2 (GPR43)4 expression has been shown to be expressed in higher magnitudes within immune
cells, has been hypothesized to be involved in the modulation of pro- and anti-inflammatory
mediators, such as prostaglandin E2 and is involved in neutrophil chemotaxis in mice. GPR43
is involved in the process of differentiation of progenitor immune cells into monocytes and
macrophages, a key component of host defense. In addition, highly selective expression of
GPR43 in polymorphonuclear cells point to strong role in chemotaxis and recruitment of
immune cells to foci of bacterial infection. Short chain fatty acids also activate GPR43
receptors on intestinal epithelial cells with rapid production of secondary chemokine and
cytokines after being challenged with inflammation and infection, and likely aid in the
coordinated immune response. GP43 is likely an essential component of the phagocytic
chemotaxis that maintains normal intestinal immune defense. In a model of acute colitis,
GPR43 knockout mice demonstrated increased mortality. The authors concluded that GPR43
deficiency likely suppressed the role of immune cells within the gut immune milieu leading
to death from sepsis related complications. Conversely, in a chronic colitis model, GPR43
deficient knockout mice demonstrated reduced colonic inflammation, without overwhelming
infection, the authors concluded that GPR43 has an unfavorable role in the manifestation of
chronic inflammatory conditions. These findings were confirmed with at least one later
study. In humans, fetal membrane expression of GPR43 was higher in parturients in preterm
labor with signs of infection.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |